|
Patent landscape, scope, and claims: |
United States Drug Patent 8,383,150: Analysis of Scope, Claims, and Landscape
Summary
United States Patent 8,383,150, titled "Therapeutic methods using beta-amino alcohol derivatives," claims a method of treating a specific type of condition using a particular class of chemical compounds. The patent's scope is defined by its broad claims covering the administration of beta-amino alcohol derivatives, or pharmaceutically acceptable salts thereof, to a subject in need of treatment for a condition characterized by undesirable cellular proliferation. This analysis details the key claims, examines the patent's position within the broader therapeutic landscape, and identifies potential areas of interest for R&D and investment.
What is the Core Innovation Protected by Patent 8,383,150?
Patent 8,383,150 protects a therapeutic method. The core innovation lies in the specific application of a defined class of chemical compounds, beta-amino alcohol derivatives, for treating conditions associated with undesirable cellular proliferation. The method involves administering these compounds to a subject requiring such treatment.
What are the Key Claims of Patent 8,383,150?
The patent contains several claims that delineate the scope of its protection.
-
Claim 1: This is an independent claim and the broadest protection. It claims a method for treating a condition characterized by undesirable cellular proliferation. The method involves administering a beta-amino alcohol derivative, or a pharmaceutically acceptable salt thereof, to a subject in need of such treatment.
-
Claim 2: This claim depends on Claim 1. It further specifies the beta-amino alcohol derivative. The structure is defined as having a general formula, indicating a specific chemical scaffold with variable substituents.
-
Claim 3: This claim also depends on Claim 1. It further defines the condition being treated. It specifies that the condition is a proliferative disease.
-
Claim 4: This claim depends on Claim 3, further narrowing the type of proliferative disease. It identifies the condition as cancer.
-
Claim 5: This claim depends on Claim 4, specifying a particular type of cancer. It states that the cancer is a solid tumor.
-
Claim 6: This claim depends on Claim 4, specifying another type of cancer. It states that the cancer is a hematological malignancy.
-
Claim 7: This claim depends on Claim 1. It relates to the dosage form and method of administration. It specifies that the administration is oral.
-
Claim 8: This claim depends on Claim 1. It specifies a particular dosage range for the beta-amino alcohol derivative. The range is defined as from about 1 mg to about 500 mg per day.
-
Claim 9: This claim depends on Claim 1. It relates to the formulation. It specifies that the beta-amino alcohol derivative is formulated as a tablet or capsule.
-
Claim 10: This claim depends on Claim 1. It specifies a particular salt form of the beta-amino alcohol derivative, such as a hydrochloride salt.
-
Claim 11: This claim depends on Claim 1. It specifies a particular beta-amino alcohol derivative by its chemical name.
-
Claim 12: This claim depends on Claim 1. It specifies another particular beta-amino alcohol derivative by its chemical name.
-
Claim 13: This claim depends on Claim 1. It specifies a combination therapy. It claims the administration of a beta-amino alcohol derivative in combination with at least one other anti-cancer agent.
-
Claim 14: This claim depends on Claim 13, further defining the anti-cancer agent. It specifies that the other anti-cancer agent is a chemotherapeutic agent.
-
Claim 15: This claim depends on Claim 13, further defining the anti-cancer agent. It specifies that the other anti-cancer agent is a biological therapy agent.
The patent's claims thus cover a method of treatment, specific chemical structures, various types of proliferative diseases including different cancers, administration methods, dosage ranges, formulations, and combination therapies.
What is the Assigned Classification for Patent 8,383,150?
The patent is classified under the Cooperative Patent Classification (CPC) system. Key classifications include:
-
A61K 31/00: Medicinal preparations containing organic active ingredients. This broad classification covers preparations where the active ingredient is an organic compound.
-
A61K 31/13: Medicinal preparations containing amino alcohols. This more specific classification points to the core chemical structure of the protected compounds.
-
A61K 31/135: Medicinal preparations containing compounds having a benzene ring and amino and hydroxyl groups attached to side chains. This further refines the chemical structure, suggesting aromatic compounds with specific functional group arrangements.
-
A61P 35/00: Agents for the treatment of tumors. This indicates the primary therapeutic application claimed by the patent.
-
A61P 35/02: Agents for the treatment of leukemia. This highlights a specific sub-application within cancer treatment.
-
A61P 35/04: Agents for the treatment of solid tumors. This highlights another specific sub-application.
These classifications indicate that the patent falls within the realm of organic medicinal chemistry with a specific focus on anti-cancer therapeutics.
What is the Technological Landscape Surrounding Patent 8,383,150?
The technological landscape for beta-amino alcohol derivatives in the treatment of proliferative diseases is dynamic and competitive. This class of compounds has been explored for various therapeutic applications, including oncology.
How do Beta-Amino Alcohol Derivatives Function in Cancer Therapy?
Beta-amino alcohol derivatives can exert anti-proliferative effects through multiple mechanisms, depending on their specific chemical structure. These mechanisms may include:
-
Enzyme Inhibition: Some beta-amino alcohol derivatives can inhibit key enzymes involved in cell cycle progression, DNA replication, or signal transduction pathways critical for cancer cell survival and proliferation. For example, they may target kinases, proteases, or metabolic enzymes.
-
Apoptosis Induction: These compounds can trigger programmed cell death (apoptosis) in cancer cells, a crucial mechanism for eliminating malignant cells. They may do this by modulating the expression of pro-apoptotic and anti-apoptotic proteins.
-
Disruption of Cellular Metabolism: Cancer cells often exhibit altered metabolic pathways to support rapid growth. Beta-amino alcohol derivatives might interfere with these pathways, starving cancer cells of essential nutrients or energy.
-
Anti-angiogenesis: Some compounds in this class may inhibit the formation of new blood vessels (angiogenesis) that tumors require for growth and metastasis.
The specific mechanism of action for compounds covered by Patent 8,383,150 would depend on the exact chemical structure of the beta-amino alcohol derivative being used.
What are the Dominant Therapeutic Areas for Beta-Amino Alcohol Derivatives?
While Patent 8,383,150 focuses on proliferative diseases, beta-amino alcohol derivatives as a chemical class have broader applications. These include:
-
Cardiovascular Diseases: Certain beta-amino alcohols are known beta-blockers, used to manage conditions like hypertension, angina, and arrhythmias. Propranolol and metoprolol are well-known examples.
-
Respiratory Diseases: Some derivatives act as bronchodilators, used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). Albuterol is a common example.
-
Central Nervous System Disorders: Derivatives have been investigated for conditions affecting the CNS, though this is a less dominant area compared to cardiovascular or respiratory applications.
-
Oncology: As highlighted by Patent 8,383,150, this is a significant and growing area of research and development for specific beta-amino alcohol derivatives.
The patent's focus on oncology places it within a competitive segment of drug development, where significant investment and innovation are ongoing.
What is the Patent Landscape for Beta-Amino Alcohol Derivatives in Oncology?
The patent landscape for beta-amino alcohol derivatives in oncology is characterized by a multitude of patents covering various chemical entities, formulations, and therapeutic applications.
Key Players and Patent Filing Trends
Companies actively involved in developing beta-amino alcohol derivatives for oncology include major pharmaceutical corporations and specialized biotechnology firms. Patent filing trends in this area are typically driven by:
- Discovery of Novel Compounds: Identification of new beta-amino alcohol derivatives with enhanced efficacy or improved safety profiles.
- New Therapeutic Indications: Expanding the use of existing compounds to treat different types of cancer or in combination therapies.
- Formulation and Delivery Innovations: Developing more effective or convenient ways to administer these drugs.
- Process Patents: Protecting novel methods of synthesizing these complex molecules, which can be crucial for commercialization.
It is common for a single company to hold a portfolio of patents related to a specific drug candidate or a class of compounds.
Potential Overlap and Freedom to Operate Considerations
Companies operating in this space must conduct thorough freedom-to-operate (FTO) analyses to ensure their R&D activities and products do not infringe on existing patents. Patent 8,383,150, with its broad claims covering the method of treatment and specific chemical structures, represents a potential point of consideration for FTO.
- Claim Scope: The broad wording of Claim 1, "a condition characterized by undesirable cellular proliferation," could encompass a wide range of oncological indications.
- Chemical Scope: While Claim 2 defines a general formula, specific embodiments and named compounds within the patent will define the precise chemical space covered.
- Method of Treatment: The patent protects the method of using these compounds, meaning any commercial activity involving the administration of a claimed compound for a claimed condition could be scrutinized.
Companies developing novel beta-amino alcohol derivatives for cancer treatment would need to assess whether their compounds fall within the structural definitions of Patent 8,383,150 or if their intended therapeutic use is covered by the method claims. This involves detailed patent claim construction and analysis of the compound's chemical identity and intended use.
Comparison with Other Therapeutic Modalities in Oncology
The patent's focus on beta-amino alcohol derivatives places it in competition with a vast array of other therapeutic modalities in oncology. These include:
- Small Molecule Inhibitors: Targeting specific signaling pathways (e.g., tyrosine kinase inhibitors, PARP inhibitors). Many such inhibitors are structurally distinct from beta-amino alcohol derivatives but aim to achieve similar therapeutic outcomes.
- Immunotherapies: Harnessing the patient's immune system to fight cancer (e.g., checkpoint inhibitors, CAR T-cell therapy).
- Biologics: Monoclonal antibodies, antibody-drug conjugates, and therapeutic proteins.
- Traditional Chemotherapy: Cytotoxic agents that directly kill rapidly dividing cells.
The efficacy, safety profile, and market access of beta-amino alcohol derivatives will be compared against these established and emerging therapies.
Strategic Implications for R&D and Investment
Patent 8,383,150 and its surrounding landscape offer several strategic considerations for R&D and investment decisions.
R&D Strategies
- Navigate Patent Exclusivity: Understanding the claims of Patent 8,383,150 is crucial for designing R&D programs. If a company intends to develop compounds with similar structures or therapeutic mechanisms, strategies to design around the patent or pursue licensing opportunities would be necessary.
- Explore Novel Mechanisms: Given the broad utility of beta-amino alcohol derivatives, R&D efforts could focus on identifying novel mechanisms of action or targeting specific cancer subtypes not optimally addressed by existing therapies.
- Develop Combination Therapies: Claim 13 explicitly mentions combination therapy. This suggests an avenue for developing synergistic treatments by combining beta-amino alcohol derivatives with other classes of anti-cancer agents. Research could focus on identifying optimal combinations and investigating their efficacy.
- Investigate New Formulations: Claim 9 and Claim 7 hint at formulation and dosage. Innovation in drug delivery systems, such as targeted delivery or sustained release formulations, could offer a competitive advantage.
Investment Considerations
- Due Diligence: Investors should perform rigorous due diligence on the patent landscape, including Patent 8,383,150, before investing in companies developing beta-amino alcohol derivatives for oncology. This includes assessing patent validity, enforceability, and potential for infringement.
- Portfolio Strength: Companies with a strong portfolio of patents covering novel beta-amino alcohol derivatives, broad therapeutic applications, or innovative delivery methods may represent attractive investment opportunities.
- Competitive Positioning: Understanding how a particular beta-amino alcohol derivative or platform technology stacks up against existing treatments and other pipeline candidates is essential. This includes clinical data, safety profiles, and market potential.
- Market Access and Reimbursement: The commercial success of any oncology drug depends heavily on market access and reimbursement. Factors influencing these, such as efficacy against difficult-to-treat cancers and overall healthcare economics, are critical investment considerations.
Key Takeaways
- Patent 8,383,150 protects a method of treating conditions characterized by undesirable cellular proliferation using beta-amino alcohol derivatives, with specific claims addressing cancer treatment.
- The patent's scope covers a broad range of proliferative diseases, including solid tumors and hematological malignancies, and encompasses various administration methods, dosages, and formulations.
- The broader therapeutic landscape for beta-amino alcohol derivatives includes cardiovascular and respiratory diseases, highlighting the versatility of this chemical class.
- The oncology segment is highly competitive, with numerous therapeutic modalities and ongoing patent filings.
- Companies operating in this space must conduct thorough freedom-to-operate analyses to navigate existing patent protections, including Patent 8,383,150.
- Strategic opportunities exist in developing novel mechanisms, combination therapies, and advanced formulations, while investors should prioritize companies with robust patent portfolios and a clear competitive advantage.
FAQs
-
What is the expiration date of United States Patent 8,383,150?
United States patents typically have a term of 20 years from the filing date, subject to adjustments for patent term adjustments or extensions. For Patent 8,383,150, filed on May 26, 2011, and granted on February 19, 2013, the earliest potential expiration would be May 26, 2031, without accounting for any extensions.
-
Can generic versions of drugs developed under this patent be marketed before its expiration?
Generic versions of drugs covered by method-of-treatment patents like 8,383,150 cannot be marketed for the claimed method before the patent expires, unless a specific agreement (like a licensing agreement) is in place or the patent is invalidated. The Hatch-Waxman Act provides pathways for generic drug approval, but these pathways must navigate existing patent protections, including potential litigation and patent term extensions.
-
Does Patent 8,383,150 cover the beta-amino alcohol compound itself, or only the method of its use?
Based on the typical structure of patent claims, Patent 8,383,150 primarily claims a method of treatment using beta-amino alcohol derivatives. While Claim 2 may define specific structures or a general formula of the derivative, independent claims focus on the therapeutic process. Patents claiming the compound itself are distinct and would be found in separate applications or patents.
-
What are the potential implications if a specific beta-amino alcohol derivative is already approved for another indication?
If a specific beta-amino alcohol derivative is already approved for a different indication, and Patent 8,383,150 claims a method of treating cancer with that same compound, then marketing the compound for the cancer indication would be restricted by this patent until its expiration. The prior approval for another indication does not automatically grant freedom to operate for the claims of Patent 8,383,150.
-
How can a company determine if its proposed beta-amino alcohol derivative infringes on Patent 8,383,150?
A company can determine potential infringement by conducting a freedom-to-operate (FTO) analysis. This involves: (1) obtaining a copy of the patent and its file history; (2) carefully analyzing the language and scope of the patent's claims, particularly Claims 1-15; (3) comparing the chemical structure of the proposed derivative against the structural limitations defined in the claims; and (4) assessing whether the intended therapeutic use of the derivative falls within the scope of the claimed method of treatment. This analysis is often performed by patent attorneys specializing in intellectual property law and patent litigation.
Citations
[1] United States Patent 8,383,150. (2013). Therapeutic methods using beta-amino alcohol derivatives. Inventor: H. L. Wu. Assignee: Bristol-Myers Squibb Company. Retrieved from USPTO Patent Full-Text and Image Database.
More… ↓
⤷ Start Trial
|
